Tesamorelin + Ipamorelin Blend (10 mg Vial) Dosage Protocol
Tesamorelin + Ipamorelin blend pairs the visceral-fat-targeting GHRH analog (Tesamorelin) with the selective, clean GH pulse of Ipamorelin. No cortisol, no prolactin elevation — the premium GH secretagogue combination.
âš¡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = ~3.33 mg/mL total)
Route: Subcutaneous (SC) | Frequency: Once daily
| Week | Tesamorelin Dose | Ipamorelin Dose (equal, 1:1) | Units (mL) |
|---|---|---|---|
| Weeks 1–2 | 250 mcg (0.25 mg) | 250 mcg (0.25 mg) | 15 units (0.15 mL) |
| Weeks 3–4 | 500 mcg (0.5 mg) | 500 mcg (0.5 mg) | 30 units (0.30 mL) |
| Weeks 5–6 | 1000 mcg (1.0 mg) | 1000 mcg (1.0 mg) | 60 units (0.60 mL) |
| Weeks 7–10 | 1500 mcg (1.5 mg) | 1500 mcg (1.5 mg) | 90 units (0.90 mL) |
| Weeks 11–16 | 2000 mcg (2.0 mg) | 2000 mcg (2.0 mg) | 120 units (1.20 mL) |
Corrected for the 1:1 vial: every unit holds equal amounts of both peptides (16.67 mcg each), so each draw delivers the same amount of Ipamorelin as Tesamorelin. Amounts follow the Tesamorelin schedule. Draws above 100 units exceed a 1 mL syringe; split them into two injections.
Note: At 3.0 mL reconstitution, 1 mL holds 1.67 mg tesamorelin and 1.67 mg ipamorelin.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; follow a product-specific validated use-by period.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration.
| Item | Quantity |
|---|---|
| Peptide Vials (Tesamorelin 5 mg + Ipamorelin 5 mg, 10 mg blend each) | 8 weeks ≈ 10 vials 12 weeks ≈ 19 vials 16 weeks ≈ 31 vials |
| Insulin Syringes (U‑100) | Per week: 7 syringes (1/day) 8 weeks: 56 syringes 12 weeks: 84 syringes 16 weeks: 112 syringes |
| Bacteriostatic Water (10 mL bottles) | 8 weeks (10 vials): 30 mL → 3 × 10 mL bottles 12 weeks (19 vials): 57 mL → 6 × 10 mL bottles 16 weeks (31 vials): 93 mL → 10 × 10 mL bottles |
| Alcohol Swabs | Per week: 14 swabs (2/day) 8 weeks: 112 swabs → recommend 2 × 100‑count boxes 12 weeks: 168 swabs → recommend 2 × 100‑count boxes 16 weeks: 224 swabs → recommend 3 × 100‑count boxes |
Protocol Overview
The Tesamorelin + Ipamorelin (no-DAC) blend is the appetite-stimulating cousin of Ipamorelin + Ipamorelin. Same GHRH+GHRP synergy with stronger GH pulse, but with significant appetite increase via ghrelin pathway activation.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 28 days, protect from light |
Important Notes
How This Works
Same GHRP + GHRH synergy as the Ipamorelin/Ipamorelin blend, but using Tesamorelin instead. Result is a stronger GH pulse with some cortisol and appetite stimulation. Used when appetite increase is desirable.
Potential Benefits & Side Effects
Potential Benefits
- Clean pulsatile GH release — no cortisol or prolactin elevation.
- Appetite stimulation via Tesamorelin.
Side Effect Profile
- Well-tolerated — selective GH release only.
- Injection-site reactions possible.
- Injection-site reactions.
Lifestyle Factors
- Avoid eating for 30+ min post-dose.
- Plan meals to manage appetite.
Injection Technique
- Subcutaneous, rotate sites with each dose.